Research results from 45 studies across more than 20 various solid tumor types demonstrate the impact of Caris' approach to molecular profiling across…
Bristol Myers Squibb announced results from the primary analysis of PILOT, a multicenter, Phase 2 study evaluating Breyanzi (lisocabtagene maraleucel)…